Lixisenatide, discovered by Zealand Pharma and licensed to Sanofi, is a once-daily GLP-1 receptor agonist for Type-2 diabetes .
Sanofi is set to complete Phase III development of the drug as a new treatment for the disease.
The MAA includes data from the GetGoal Phase III program, comprising nine studies and over 4,300 patients.
The GetGoal program provides data to support lixisenatide in treating adults with Type-2 diabetes mellitus.